基于重组组织因子凝血活酶试剂的研究进展  

Recombinant tissue factor-based thromboplastin reagents: research progress

作　　者：孙金霞[1] 郭振中[2] 孙雷[1] 景元霞[1] 黄耀江[1,3] 

机构地区：[1]中央民族大学生命与环境科学学院,北京100081 [2]冀中能源峰峰集团总医院,邯郸056200 [3]中国民族地区环境资源保护研究所,北京100081

出　　处：《第二军医大学学报》2012年第2期220-223,共4页Academic Journal of Second Military Medical University

基　　金：高等学校学科创新引智计划(B08044);国家“985”及“211”工程项目(CUN985-3-3);北京市校企合作产学研项目~~

摘　　要：在20世纪90年代出现可纯化组织因子(TF)之前,凝血活酶试剂由人或动物组织粗提物制成。近年来,已经改用高度纯化的重组组织因子(rTF)或可溶性组织因子(sTF)来制备凝血活酶试剂。本文综述了国内外基于重组组织因子的凝血酶原试剂研发技术的发展历程,归纳重组凝血活酶试剂优于组织提取物试剂的特点,分析凝血活酶的发展趋势,并指出高灵敏性和稳定性重组凝血活酶是未来凝血活酶的发展方向。Thromboplastin reagents were made from natural tissues of human or animals before the emergence of tissue factor（TF） which can be purified in 1990s.In recent years,highly purified recombinant tissue factor（rTF） or soluble tissue factor（sTF） has been used to prepare thromboplastin reagents.This article reviewed the evolution of technique for preparing recombinant tissue factor-based thromboplastin reagents both at home and abroad,and summarized the advantages of recombinant tissue factor and analyzed the future of thromboplastin reagents.It has been pointed out that highly sensitive and stable thromboplastin reagents are needed in the future.

关 键 词：凝血活酶试剂 凝血酶原时间 组织因子 重组组织因子 可溶性组织因子 

分 类 号：R446.11[医药卫生—诊断学]